2 transcripts
SDGR
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
to submit an investigational new drug application for SGR-3515, our Wee1/Myt1 inhibitor in the first half of this year and are advancing an existing
SDGR
Earnings call transcript
NASDAQ
2023 Q2
2 Aug 23
first-in-class or best-in-class investigational medicines speaks to the power of the platform and provides us with an opportunity to advance
- Prev
- 1
- Next